New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017
Lund, Sweden, September 28, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...
Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
Lund, Sweden, July 19, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Alligator Bioscience AB Interim Report January-June 2018
Positive data for our preclinical projects Significant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoin ...
Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013
Lund, Sweden, 3 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...
Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013
Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...
Alligator Bioscience AB Interim Report January-September 2017
Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...
Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527
ALG.APV-527 – A novel bispecific antibody candidate being developed by Alligator Bioscience and Aptevo Therapeutics. Engineered to Eng ...
Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017
Lund, Sweden, September 21, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...
Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB
Research team to be led by Professor Ignacio Melero, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain Lu ...